With psychedelics going mainstream, it should come as no surprise that researchers are planning to conduct a trial evaluating the treatment of alcohol use disorder using psilocybin, which is commonly known as a magic mushroom. Director of the Pacific Neuroscience Institute Daniel Kelly, who is also a neurosurgeon, will be carrying out the trial using a new approach, which will also employ the use of a nature-themed video.
The filmmaker who created the video, Louie Schwartzberg, asserted that the film was not only historic but also truly groundbreaking work.
Prior research has shown that video can enhance a psychedelic experience induced by psilocybin, noting that it can be effective for patients who want to sort out their psychological issues. This highlights the need for new approaches, especially if one considers the inconsistent results that have been produced by the conventional treatments for addiction.
Kelly explained that there exists a long history of shamanic cultures that have successfully managed these issues using psychedelics, noting that in the ‘50s, psychedelics were the subject of therapeutic research at many established institutions, including Harvard University.
He also added that for the last two decades a renaissance in psychedelic-assisted therapy had been ongoing, explaining that as a neuroscientist, this was probably the most interesting thing going on in the field as there was the potential to help so many individuals who were in need.
During a regular psychedelic therapy session with psilocybin, patients are placed in a calm space where they can relax before a dose of the active ingredient is administered. They are then monitored by trained guides as they sink into a hallucinogenic state for a few hours, which is popularly referred to as a trip.
Before they join the treatment program, patients are interviewed and screened for suitability, after which they undergo integration sessions with a therapist, allowing them to better comprehend their issues, with the objective being to alter both their outlook as well as their behavior.
Schwartzberg became a believer in the healing power of nature after his own experience with psilocybin and came up with the idea of introducing nature visuals into a clinical setting after he saw patients wearing eye-shades. His acquaintance with Kelly will help actualize his idea through the TRIP program launched Kelly, which focuses on treatment and research in psychedelics.
Kelly noted that their hypothesis was that patients who experienced the nature-themed video were more likely to try dealing with their drinking by decreasing their intake or stopping to drink altogether.
There is rapid progress being made in the arena of psychedelic research. Further proof of this is the announcement by XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) that in 2021, the company would be shifting gears from the laboratory to clinical trials.
NOTE TO INVESTORS: The latest news and updates relating to XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) are available in the company’s newsroom at https://ibn.fm/XPHYF
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire is part of the InvestorBrandNetwork.